Negative symptoms: a path analytic approach to a double-blind, placebo- and haloperidol-controlled clinical trial with olanzapine.

OBJECTIVE The authors investigated whether primary negative symptoms of schizophrenia are enduring or treatment-responsive. METHODS Previously, a double-blind, random-assignment trial of the novel antipsychotic olanzapine (in low, medium, and high dose ranges), placebo, or haloperidol (10-20 mg/day) for 335 schizophrenic inpatients was conducted for up to 52 weeks. Changes in the treatment groups from baseline to endpoint in summary scores on the Scale for the Assessment of Negative Symptoms (SANS) and several secondary measures were compared. This article describes a path analysis to determine to what extent the total treatment effect on negative symptoms was direct or indirect (i.e., mediated by differential effects on positive symptoms, extrapyramidal symptoms, or mood). RESULTS Significantly greater improvement was achieved with high-dose olanzapine than with placebo or haloperidol. Olanzapine had a significantly greater direct effect than placebo on all SANS dimensions except anhedonia-asociality. Olanzapine also demonstrated a significantly greater direct effect than haloperidol on negative symptoms, especially on the dimensions of affective flattening and avolition-apathy. Olanzapine's superior effects were replicated in a subgroup with SANS-defined prominent negative symptoms (N = 116) and a subgroup with a BPRS-defined cross-sectional proxy for the deficit state (N = 117). CONCLUSIONS These results suggest that the negative symptoms of schizophrenia are directly responsive to treatment. The significantly greater direct and indirect effects of olanzapine than of haloperidol on negative symptoms are likely related to olanzapine's pleotrophic pharmacology, which includes dopaminergic, serotonergic, muscarinic, and adrenergic activities. The results contribute to the hypothesis that negative symptoms may be under the influence of several neurotransmitters within one or more neuroanatomic circuits.

[1]  Philip Seeman,et al.  Radioreceptor Binding Profile of the Atypical Antipsychotic Olanzapine , 1996, Neuropsychopharmacology.

[2]  V. Peralta,et al.  Negative symptoms in schizophrenia: a confirmatory factor analysis of competing models. , 1995, The American journal of psychiatry.

[3]  B. Kirkpatrick,et al.  Drug development and the deficit syndrome of schizophrenia , 1995, Biological Psychiatry.

[4]  R. Conley,et al.  Patient response and resource management: another view of clozapine treatment of schizophrenia. , 1995, The American journal of psychiatry.

[5]  N C Andreasen,et al.  Symptoms of Schizophrenia: Methods, Meanings, and Mechanisms , 1995 .

[6]  N. Andreasen,et al.  A longitudinal study of symptom dimensions in schizophrenia. Prediction and patterns of change. , 1995, Archives of general psychiatry.

[7]  W. Eaton,et al.  Structure and course of positive and negative symptoms in schizophrenia. , 1995, Archives of general psychiatry.

[8]  S Pollack,et al.  Clinical effects of clozapine in chronic schizophrenia: response to treatment and predictors of outcome. , 1994, The American journal of psychiatry.

[9]  R. Conley,et al.  Clozapine response varies in deficit vs non-deficit schizophrenic subjects , 1994, Biological Psychiatry.

[10]  R. Tandon,et al.  Covariance of positive and negative symptoms during neuroleptic treatment in schizophrenia: A replication , 1993, Biological Psychiatry.

[11]  R. Tandon,et al.  POSITIVE AND NEGATIVE SYMPTOMS COVARY DURING CLOZAPINE TREATMENT IN SCHIZOPHRENIA , 1993 .

[12]  R. Buchanan,et al.  Case identification and stability of the deficit syndrome of schizophrenia , 1993, Psychiatry Research.

[13]  N. Andreasen,et al.  Clozapine's effect on negative symptoms in treatment-refractory schizophrenics , 1993, Schizophrenia Research.

[14]  J. Kane,et al.  Do Negative Symptoms Respond to Pharmacological Treatment? , 1989, British Journal of Psychiatry.

[15]  N. Mimica,et al.  Scale for the Assessment of Negative Symptoms (SANS)* , 1989, British Journal of Psychiatry.

[16]  T. Barnes.  A Rating Scale for Drug-Induced Akathisia , 1989, British Journal of Psychiatry.

[17]  R. Tandon,et al.  Mutability and relationship between positive and negative symptoms during neuroleptic treatment in schizophrenia , 1989, Biological Psychiatry.

[18]  R. Tandon,et al.  Mutability and relationship between positive and negative symptoms during neuroleptic treatment in schizophrenia , 1989, Biological Psychiatry.

[19]  G Honigfeld,et al.  Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. , 1988, Archives of general psychiatry.

[20]  D. Hommer,et al.  Effect of pimozide on positive and negative symptoms in schizophrenic patients: are negative symptoms state dependent? , 1987, Neuropsychobiology.

[21]  H. Meltzer,et al.  The Effect of Neuroleptics and Other Psychotropic Drugs on Negative Symptoms in Schizophrenia , 1986, Journal of clinical psychopharmacology.

[22]  N. Andreasen,et al.  Evaluation of positive and negative symptoms in schizophrenia , 1986 .

[23]  N C Andreasen,et al.  Negative v positive schizophrenia. Definition and validation. , 1982, Archives of general psychiatry.

[24]  T. Crow,et al.  Molecular pathology of schizophrenia: more than one disease process? , 1980, British medical journal.

[25]  G. Simpson,et al.  A RATING SCALE FOR EXTRAPYRAMIDAL SIDE EFFECTS , 1970, Acta psychiatrica Scandinavica. Supplementum.

[26]  J. Overall,et al.  The Brief Psychiatric Rating Scale , 1962 .

[27]  C. Halldin,et al.  A PET Study of 5-HT2 and D2 Dopamine Receptor Occupancy Induced by Olanzapine in Healthy Subjects , 1997, Neuropsychopharmacology.

[28]  G. Tollefson,et al.  Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. , 1996, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology.

[29]  N. Andreasen,et al.  Clozapine's effect on negative symptoms in treatment-refractory schizophrenics☆ , 1994 .

[30]  L. Opler,et al.  Psychopharmacologic treatment of negative schizophrenic symptoms. , 1994, Comprehensive psychiatry.

[31]  R. Buchanan,et al.  Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia. , 1994, The American journal of psychiatry.

[32]  S. Goldberg.  Negative and deficit symptoms in schizophrenia do respond to neuroleptics. , 1985, Schizophrenia bulletin.